The informative value of non-invasive liver fibrosis markers in patients with nonalcoholic fatty liver disease


Cite item

Full Text

Abstract

Aim. To estimate the diagnostic and informative value of clinical and laboratory parameters in the development and progression of liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) to enhance efficiency of their treatment. Subjects and methods. An open-label case-control study included 77 patients with NAFLD. Clinical and laboratory examinations were done. To search for additional noninvasive fibrosis markers, the investigators studied the serum concentrations of insulin, leptin, adiponectin, matrix metalloproteinase-9 (MMP-9) and its inhibitors, such as tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) and TIMP-2. All the patients underwent elastometry to assess the degree of liver fibrosis with the Metavir scale with the use of a Fibroscan machine. Results. The serum levels of low-density lipoproteins, glucose, MMP-9, and leptin proved to be most informative in assessing the progression of the initial stages (1-2) of fibrosis, as were the increased liver size detected by physical examination, systolic blood pressure, carbohydrate metabolic disorders, alanine/aspartate aminotransferase levels, waist-to-hip ratio, TIMP-1, and TIMP-2 in evaluating the progression of Stage II fibrosis 2 to Stage 3. Conclusion. The clinical and laboratory parameters can serve as reliable noninvasive markers that reflect the progression of fibrotic changes in liver tissue.

References

  1. Targher G, Byrne CD. Obesity: Metabolically healthy obesity and NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13(8):442-444. doi: 10.1038/nrgastro.2016.104
  2. Mantovani A, Rigamonti A, Bonapace S, Bolzan B, Pernigo M, Morani G, Franceschini L, Bergamini C, Bertolini L, Valbusa F, Rigolon R, Pichiri I, Zoppini G, Bonora E, Violi F, Targher G. Nonalcoholic Fatty Liver Disease Is Associated With Ventricular Arrhythmias in Patients With Type 2 Diabetes Referred for Clinically Indicated 24-Hour Holter Monitoring. Diabetes Care. 2016;39(8):1416-1423. doi: 10.2337/dc16-0091
  3. Jahn D, Rau M, Wohlfahrt J, Hermanns HM, Geier A. Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies. Dig Dis. 2016;34(4):356-363. doi: 10.1159/000444547
  4. Fuchs M, Schnabl B. Editors’ Introduction to the NAFLD and NASH Special Issue. Dig Dis Sci. 2016;61(5):1211-1213. doi: 10.1007/s10620-016-4152-z
  5. Гаус О.В., Ахмедов В.А. Оценка прогностических факторов развития желчнокаменной болезни у лиц с метаболическим синдромом. Экспериментальная и клиническая гастроэнтерология. 2014;(11):46-50.
  6. Гаус О.В., Ахмедов В.А. Клинико-лабораторные и сонографические предикторы успешной консервативной терапии у больных с желчнокаменной болезнью в ассоциации с метаболическим синдромом. Экспериментальная и клиническая гастроэнтерология. 2015;(7):18-23.
  7. Fialho A, Fialho A, Thota P, McCullough AJ, Shen B. Small Intestinal Bacterial Overgrowth Is Associated with Non-Alcoholic Fatty Liver Disease. J Gastrointestin Liver Dis. 2016;25(2):159-165. doi: 10.15403/jgld.2014.1121.252.iwg
  8. Abenavoli L, Di Renzo L, De Lorenzo A. Body Composition and Non-alcoholic Fatty Liver Disease. J Lifestyle Med. 2016;6(1):47-48. doi: 10.15280/jlm.2016.6.1.47
  9. Sporea I, Mare R, Lupușoru R, Sima A, Sirli R, Popescu A, Timar R. Liver Stiffness Evaluation by Transient Elastography in Type 2 Diabetes Mellitus Patients with Ultrasound-proven Steatosis. J Gastrointestin Liver Dis. 2016;25(2):167-174. doi: 10.15403/jgld.2014.1121.252.lsf
  10. Gancheva S, Bierwagen A, Kaul K, Herder C, Nowotny P, Kahl S, Giani G, Klueppelholz B, Knebel B, Begovatz P, Strassburger K, Al-Hasani H, Lundbom J, Szendroedi J, Roden M; German Diabetes Study (GDS) Group. Variants in Genes Controlling Oxidative Metabolism Contribute to Lower Hepatic ATP Independent of Liver Fat Content in Type 1 Diabetes. Diabetes. 2016;65(7):1849-1857. doi: 10.2337/db16-0162
  11. Jahn D, Rau M, Wohlfahrt J, Hermanns HM, Geier A. Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies. Dig Dis. 2016;34(4):356-363. doi: 10.1159/000444547
  12. Ливзан М.А., Кролевец Т.С., Лаптева И.В., Черкащенко Н.А. Неалкогольная жировая болезнь печени у лиц с абдоминальным типом ожирения. Доказательная гастроэнтерология. 2014;4:8-14. doi: 10.17116/dokgastro2014348-14
  13. Thrasher T, Abdelmalek MF. Nonalcoholic Fatty Liver Disease. N C Med J. 2016;77(3):216-219. doi: 10.18043/ncm.77.3.216
  14. Machado MV, Cortez-Pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci. 2016;17(4).pii: E481. doi: 10.3390/ijms17040481
  15. Bedossa P, Patel K. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150(8):1811-1822. doi: 10.1053/j.gastro.2016.03.008
  16. Ливзан М.А., Лаптева И.В., Миллер Т.С. Роль лептина и лептинорезистентности в формировании неалкогольной жировой болезни печени у лиц с ожирением. Экспериментальная и клиническая гастроэнтерология. 2014;108(8):27-33.
  17. Ливзан М.А., Кролевец Т.С., Лаптева И.В., Черкащенко Н.А. Лептинорезистентность у лиц с неалкогольной жировой болезнью печени, ассоциированной с ожирением и избыточной массой тела. Медицинский совет. 2015;13:58-62.
  18. Kaswala DH, Lai M, Afdhal NH.Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Dig Dis Sci. 2016;61(5):1356-1364. doi: 10.1007/s10620-016-4079-4
  19. Singh SP, Singh A, Misra D, Misra B, Pati GK, Panigrahi MK, Kar SK, Bhuyan P, Pattnaik K, Meher C, Agrawal O, Rout N, Swain M, Aich P. Risk Factors Associated With Non-Alcoholic Fatty Liver Disease in Indians: A Case-Control Study. J Clin Exp Hepatol. 2015;5(4):295-302. doi: 10.1016/j.jceh.2015.09.001
  20. Amarapurkar D, Amarapurkar A. Indications of Liver Biopsy in the Era of Noninvasive Assessment of Liver Fibrosis. J Clin Exp Hepatol. 2015;5(4):314-319. doi: 10.1016/j.jceh.2015.08.005

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies